ArticleBMJ open2025

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet's disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol.

Bettina C Geertsema-Hoeve et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.